<DOC>
	<DOCNO>NCT02468414</DOCNO>
	<brief_summary>The objective study assess safety evaluate biologic activity TARGTEPO treatment Peritoneal Dialysis patient</brief_summary>
	<brief_title>TARGTEPO Treatment Anemia PD US Trial</brief_title>
	<detailed_description>This Phase II , open-label study . Each patient administer target dose EPO deliver via TARGTEPO . The targeted dos determine accord 2 cohort follow : Group A ( 18-25 IU/Kg/day ) , Group B ( 35-45 IU/Kg/day ) . The objective evaluate safety biologic activity TARGTEPO treatment maintain Hb level within target range 9-12 g/dl . Biological activity assessment include duration TARGTEPO secretion measure serum EPO level baseline .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Adult male female subject 18 80 year age time screen visit . 2 . Subject diagnosed anemia due Chronic Kidney Disease ( CKD ) Stage 5 peritoneal dialysis treatment least 6 month . Average Hgb last month 9 12g/dL . Stable dose ESAs past month prior enrollment . 3 . Hypertensive subject stable anti HTN treatment past one month prior enrollment Systolic blood pressure ( BP ) 150 Diastolic BP 90 upon enrollment . 4 . Kt/V &gt; 1 . 5 . INR ≤ 1.2 . 6 . Serum albumin &gt; 3.2 . 7 . Subjects adequate iron store ( transferrin saturation &gt; 20.0 % and/or ferritin &gt; 100 ng/ml ) . 8 . Capable provide sign write informed consent participate study . 1 . Uncontrolled hypertension ( define diastolic blood pressure &gt; 110 mmHg systolic blood pressure &gt; 180 mmHg screening ) . 2 . Subjects receive oral anticoagulation treatment ( e.g . warfarin ) . 3 . Subjects receive acetylsalicylic acid ( ASA ) 325 mg/day patient receive ASA treatment 100mg/d 325 mg/d discontinue 1 week prior Harvest Implantation Procedure . 4 . Congestive heart failure ( New York Heart Association functional class III IV ) . 5 . Grand mal seizure within 2 year Screening Visit . 6 . Clinical evidence severe hyperparathyroidism define parathyroid hormone ( PTH ) level &gt; 10 time upper normal limit . 7 . Major surgery within 12 week Screening Visit . 8 . Systemic hematologic disease ( e.g. , sickle cell anemia , thalassemia ( exclude thalassemia minor ) , myelodysplastic syndrome , hematologic malignancy , myeloma , hemolytic anemia ) . 9 . Current systemic infection , active inflammatory disease , malignancy active treatment . 10 . Subjects know test positive time past antibody erythropoietic protein . 11 . Subject history malignancy within past 2 year prior Screening Visit , exception basal cell carcinoma . 12 . Subjects concurrent severe and/or uncontrolled medical condition could compromise participation study ( i.e . active infection , uncontrolled diabetes , uncontrolled hypertension , congestive heart failure , unstable angina , ventricular arrhythmia , active ischemic heart disease , myocardial infarction within six month , uncompensated cirrhosis , active upper gastrointestinal ( GI ) tract ulceration ) . 13 . Subject currently enrol , yet complete period least 30 day five halflives investigational drug whichever longer , since end investigational device drug trial ( ) prior Screening Phase . 14 . Psychiatric , addictive , disorder compromise ability provide inform consent participation study . 15 . Female subject childbearing potential male agree use acceptable method contraception study . 16 . Pregnant lactate female subject . 17 . Chronic alcoholic drug abuse subject . 18 . Steroid immunosuppressive treatment ( topical inhale steroid ) . 19 . Subjects unwilling unable comply study procedure . 20 . EPOnaïve subject . 21 . Known sensitivity gentamicin amphotericin . 22 . History chronic active hepatitis B and/or C infection positive serology screening , know positive Human Immunodeficiency Virus ( HIV ) positive serology screen . 23 . Subject blood transfusion within 84 day prior Screening Visit . 24 . Subject date renal transplantation . 25 . Refer United States Product Insert ( USPI ) DepoMedrol ( DM ) Methylprednisolone Acetate Injectable ( Appendix A ) concomitant drug take patient , interaction DM warrant exclusion protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Anemia</keyword>
</DOC>